Patrick Mavingui

Title: Patrick Mavingui: Innovator in Vaccine Development

Introduction

Patrick Mavingui is a notable inventor based in Sainte Clotilde la Reunion, France. He has made significant contributions to the field of vaccine development, particularly in relation to the Zika virus. His innovative work focuses on creating vaccine compositions that utilize an attenuated mutant Zika virus.

Latest Patents

Mavingui holds a patent for vaccine compositions comprising an attenuated mutant Zika virus. This invention introduces mutations at specific positions that eliminate the N-glycosylation site on the E protein of the epidemic strain. This modification is crucial as it prevents the generation of auto-antibodies that can lead to Guillain-Barre syndrome. Additionally, the inventors have engineered further mutations that significantly reduce the cytopathic effects of the virus while maintaining its ability to produce high titers. Specifically, the patent relates to an attenuated mutant Zika virus that includes a protein E of the epidemic strain, wherein at least one amino acid residue at positions 152, 156, or 158 is mutated.

Career Highlights

Throughout his career, Patrick Mavingui has worked with esteemed institutions such as Inserm (Institut National de la Santé et de la Recherche Médicale) and Université de la Réunion Saint Denis. His work in these organizations has allowed him to advance his research and contribute to significant scientific advancements.

Collaborations

Mavingui has collaborated with notable colleagues, including Philippe Despres and Gilles Gadea. These partnerships have played a vital role in the development of his innovative vaccine compositions.

Conclusion

Patrick Mavingui's contributions to vaccine development, particularly regarding the Zika virus, highlight his role as an important inventor in the field of medical research. His innovative approaches and collaborations continue to pave the way for advancements in vaccine technology.